Whether it’s developing a new chemical entity, an original product idea, a global clinical study, or undertaking a complex commercial manufacturing process, we welcome the opportunity to partner with you and transform your vision into a commercial reality. We have the capacity and agility to service a broad range of clients, from large animal health multinationals through to emerging biotech and life sciences companies. We can take on an entire project from ‘molecule to market’, or provide specific services that complement your organization’s in-house services. If you have an idea to develop or a problem to solve, the first step is to get in touch with us. We’ll listen to your requirements, and advise how we can help.
Argenta is honored to work with a vast range of clients globally – from small and medium-sized enterprises (SMEs) to some of the largest industry players. Our current client base spans Europe, the United States, Asia and beyond. We have the R&D capabilities and manufacturing scale to service the requirements of the largest multinationals. At the other end of the spectrum, we love to meet with startups and small companies with great ideas; to help them find solutions and bring their ideas to fruition. We prioritize our clients’ animal health projects and we are trusted to get the job done – transparently, efficiently, and cost-effectively.
Argenta was co-founded in 2006 by Dr Doug Cleverly, a successful New Zealand chemist with a passion for business. After working in the animal health industry in the US during the late 1990s and early 2000s, Doug returned to New Zealand to co-found ChemLabs, a small, successful contract research organization (CRO) based in Auckland. He had a vision to eventually develop a fresh new business model for the animal health industry; one that combined both research and development (R&D) and commercial-scale manufacturing. In 2006, ChemLabs purchased a nearby manufacturing facility from Nufarm Health & Sciences to expand its service offerings. Out of this acquisition, Argenta was born.
Argenta consists of a dynamic team of high-caliber scientists and other industry experts from around the world. They work passionately together to create, develop and deliver to our clients the best animal health technologies and products possible. Our key executive team is guided by a skilled board with an astute understanding of the pharmaceutical landscape. Importantly, the owners and board are completely independent of any other animal health company interests.
A formulations chemist with extensive experience in animal health, Doug co-founded Argenta in 2006. He has led Argenta from start-up phase through periods of rapid growth, to where it is today. As managing director, he continues to play a hands-on role in the business. All clients and staff have direct access to Doug, reflecting his personal commitment to every single project undertaken by the Argenta team.
After graduating with a PhD in Animal Science, Ben worked for Meat & Livestock Australia, managing on-farm and supply chain R&D programs. A stint at Rabobank to head up Food and Agribusiness Research covering Australia and New Zealand followed before Ben was promoted to be General Manager and then CEO of Rabobank’s New Zealand business from 2006 to 2015, where he led significant financial growth combined with market-leading employee engagement and customer satisfaction. Most recently, he was Head of Rural Lending with Heartland Bank. Ben joined Argenta in 2017 as Deputy CEO and oversees the execution of the company’s molecule to market strategy and supports the Argenta growth strategy developed by Doug and the Board.
Karin joined Argenta’s New Jersey subsidiary, AlcheraBio, in 2017. She is originally from The Netherlands, where she started work in the animal health industry in 1999 for a large multinational pharmaceutical company. In 2005, she became global marketing director at Intervet International, where she was responsible for the development of the companion animal vaccine portfolio that is sold in more than 100 countries. When the company became part of MSD Animal Health, Karin became a country manager in Norway, where she worked in the aqua business, as well as in the local livestock and companion animal business. In 2012 Karin moved to the USA. Throughout her career, Karin has worked with R&D and manufacturing teams on new product developments and lifecycle management projects.
Rana has worked at Argenta for 11 years, starting as an engineer in the Auckland, New Zealand, office and then moving into project and client management. She is now based in the USA, and is responsible for the development and execution of global client strategies to drive business growth and cultivate new business for Argenta. She also oversees the execution of new business via the Project Management office.
Stephen graduated with a PhD in Chemical Engineering from the University of Manchester Institute of Science and Technology in the UK and has over 25 years’ experience in the Pharmaceutical Industry. He starting his career with GSK in API Manufacturing before joining Pfizer where he held multiple leadership roles in both in the UK and in Puerto Rico. He moved to the Novartis Dundee Site in 2014, as Site Head, prior to Novartis selling its Animal Health Division to Eli Lilly (Elanco). Stephen Joined Argenta in 2017 when we purchase the Dundee Manufacturing Site from Elanco, creating a strategically important presence for Argenta in Europe.
Chris joined Argenta in 2018 in the newly formed role of Chief Financial Officer. He has nearly twenty years’ experience working in a variety of accounting roles within Big 4 and Corporate environments. He has worked in roles based in New Zealand, Australia and the United Kingdom with responsibilities covering those markets as well as Asia Pacific. He has experience working in multiple industries with a key focus on dairy, wholesale and manufacturing. He holds a Bachelor of Business majoring in Accounting and is a full member of Chartered Accountants Australia and New Zealand.
Johnny joined Argenta’s New Jersey subsidiary in February 2009. He is a Doctor of Veterinary Medicine (DVM) and also has a MSc degree in applied parasitology. After establishing a mixed animal practice in Alberta, Canada, Johnny joined the technical services organization of Merck AgVet where he played a major role in new product development projects. Prior to joining AlcheraBio, Johnny was employed by the human health organization of Merck & Co., Inc. where he was a global brand leader in several therapeutic areas.
Phil joined Argenta in 2010, bringing with him over 25 years’ experience in the food industry in senior technical and operations positions. Phil has a Bachelor of Technology (Food) from Massey University and has previously worked in Australia for Nabisco, H.J. Heinz and Simplot Australia (Edgell-Birdseye). In 2000, Phil returned home to New Zealand to run Goodman Fielder’s operations, then later worked for Pacific Equity Partners when they purchased Griffins and Tegel.
After graduating with a Bachelor’s degree in Biology from Gettysburg College, Pennsylvania, Bruce spent three years at the Stroud Water Research Center – a division of Academy of Natural Sciences of Philadelphia. From 1999 to 2007, he worked for Merck & Co. based in West Point, Pennsylvania, where he held positions in Bacterial Vaccine Manufacturing, Vaccine and Sterile Pharmaceutical Quality Assurance and Clinical QA. Bruce joined Argenta in February 2009, bringing a wealth of experience in GMP manufacturing, GMP compliance and product quality complaint investigations.
Tasi joined Argenta in 2014 after several years as a recruiter connecting people to roles they were passionate about, and to companies that fit their personal values. Her role as HR Business Partner supports our global business by building capability within our people to be a significant contributor to Argenta’s success. If you’re passionate and genuinely want to make a difference within the animal health industry, partner with us as we touch lives all over the world with the creation, development and production of the best animal health technologies and products.
After graduating from Massey University with a Bachelors Degree in Chemical Technology Graeme started his career in the Animal Health Industry in 1992. Working continuously on the Argenta New Zealand site for greater than 20 years under various company banners Graeme was one of the initial 72 team members to form Argenta in 2006. Since then has continued to support the growth and success of the New Zealand business becoming a global supplier of animal health products through improving GMP and manufacturing processes to international industry standards.
Dave is a lifelong Iowan and started work in the animal health industry in 2001 at Fort Dodge Animal Health. He worked in Operations until 2004, where he led a company-wide project covering four facilities. After successful completion of the project he joined the logistics team as a Purchasing Agent and returned to Operations in 2007. He accepted the position of Head of Site at the Riverside site in 2012. Dave joined Argenta’s USA manufacturing facility, AML Riverside, in January 2016.
Argenta is a privately-owned company headquartered in New Zealand; a nation with one of the fastest-growing biotechnology and agri-tech sectors in the world. In 2017, New Zealand was ranked second in the world by Forbes in the annual list of Best Countries for Business – and we are proud and excited to be part of this. We have US subsidiaries in New Jersey and Kansas and a state-of-the-art manufacturing facility in Fort Dodge, Iowa. In 2017, we acquired our fifth site, in Dundee, Scotland. Together, these facilities enable us to achieve significant efficiencies in product development and technology transfer, and to provide market intelligence and in-depth knowledge of market preferences in different countries as required. Having a global presence gives us the capability and scale to meet the needs of our ever-expanding global client portfolio. Find out more.